Cidara’s J&J-partnered immunotherapy could target flu and cancer

Cidara uses its Cloudbreak platform to develop targeted immunotherapies comprising small molecule drugs, peptides and a human antibody fragment. The conjugates, called drug-Fc conjugates (DFCs), are designed to inhibit specific disease targets while simultaneously engaging the immune system, allowing them to both treat and prevent disease.